Randomized Comparative Efficacy and Safety Study of Intermittent Simvastatin and Fenofibrate in Hemodialysis

This is a prospective randomized open label parallel study.

The selected patients will be randomly allocated to one of two groups

• Group I (30 patients): Patients receiving fenofibrate (100 mg) taken on dialysis days after the dialysis session (three times per week).
• Group II (30 patients): Patients receiving simvastatin (20 mg) taken on dialysis days after the dialysis session (3 times per week).

A careful history of all patients including demographic characteristics, physical examination, chief complaint, past medical history, drug history, familial history, social history, disease(s).

Monitoring Parameters:

For efficacy, the following parameters are measured:

• Lipid profile (total cholesterol, HDL, TG and LDL from Friedwald formula [10] {LDL-C= TC-[HDL + TG\\5]). (measured at baseline and every month for 4 months)
• C-reactive protein (CRP). (measured at baseline and after 4 months)
• Oxidative stress markers: oxidized LDL and human glutathione peroxidase (measured at baseline and after 4 months).

For safety: (measured at baseline and every month for 4 months)

• Observe for signs & symptoms of muscle toxicity and measure phosphocreatine kinase (CPK).
• Liver function tests: ALT, AST, ALP & albumin.
• Urea & serum creatinine. (to monitor renal function)
• Hemoglobin
• Other measurements: Body mass index (BMI), Blood Pressure, electrolytes (Sodium,potassium, calcium, phosphorous) and assess patient compliance by tablet counting.

Statistical analysis will be used to compare the effects of simvastatin and fenofibrate on lipid profile, inflammatory marker (CRP) and oxidative stress markers (oxidized LDL and glutathione peroxidase). In addition, comparing their safety on renal and hepatic functions, phosphocreatine kinase, blood pressure and blood glucose level.

Inclusion criteria

• Age ≥ 18 years.
• Chronic hemodialysis patients with 3 dialysis sessions per week.
• Lipid profile:

• Total Cholesterol ≥ 200 mg/dl or LDL ≥ 130 mg/dl.
• Triglycerides ≥ 150 mg/dl.

Exclusion criteria

• Previous intolerance to fibrates or statins.
• Use of any fibrates or statins within 6 months prior to study.
• Hypothyroidism.
• Active liver disease [unexplained persistent increase in liver enzymes (ALT & AST > 2x ULN)].
• Uncontrolled hypertension.
• History of MI or coronary bypass surgery in last 3 months.
• Muscle toxicity (Phosphocreatine kinase (CPK) > 2x ULN).
• Gall bladder disease.
• Use of any immunosuppressant or steroid.